Therapeutic Applications of Curcumin Nanomedicine Formulations in Cardiovascular Diseases

We aim to review and underline different studies and approaches looking into the promising role of nanotechnology-based drug delivery systems to deliver CUR and its derivatives in Cardiovascular diseases treatment with emphasis on their formulation properties, experimental evidence, general bioactivity, and discussing the challenges and opportunities in developing these systems

Bahare Salehi

2020

Scholarcy highlights

  • We aim to review and underline different studies and approaches looking into the promising role of nanotechnology-based drug delivery systems to deliver CUR and its derivatives in Cardiovascular diseases treatment with emphasis on their formulation properties, experimental evidence, general bioactivity, and discussing the challenges and opportunities in developing these systems
  • Authors observed that Cur-polyethylene glycol-PDLLA reduced cardiomyocyte apoptosis; besides, they reported a reduction in Bax, which plays a key role in mitochondrion-mediated apoptosis, and an increment in Bcl-2, which is an antiapoptotic protein that inhibits the oligomerization of Bax
  • CVD are an important cause of human deaths worldwide
  • Pre-clinical and clinical studies have demonstrated the effects of CUR in CVD through its anti-hypercholesterolemic and anti-atherosclerotic effects and its protective properties against cardiac ischemia and reperfusion
  • CUR nanoformulations are a therapeutic alternative in a new discovery phase
  • Future studies need to develop new CUR nanomedicine formulations and tested it in well-designed clinical studies

Need more features? Save interactive summary cards to your Scholarcy Library.